Skip to main content
. 2018 Jun 20;22(4):219–226. doi: 10.1080/19768354.2018.1473291

Figure 3.

Figure 3.

Low-dose LPS treatment prevents HD progression in R6/2 Tg mice. (A) R6/2 Tg mice were i.p. injected with either PBS (n = 8) or low-dose LPS (2 μg) (n = 8) once per week starting from 5 weeks of age for total 12 weeks. The survival rate of these mice was monitored every week after LPS treatment. (B-E) R6/2 Tg mice were i.p. injected with either PBS (n = 4) or low-dose LPS (2 μg) (n = 4) treatment from 5 to 14 weeks old. (B) The mice were also weighed weekly from 5 to 14 weeks old. (C) Mice were tested for hind limb clasping behavior at 7 weeks after LPS injection. (D) The absolute cell number of total splenocytes, macrophages, and DCs were determined at 9 weeks after LPS injection. (E) Surface expressions of CD86 and CD40 and intracellular IL12 production were analyzed in macrophages (CD11b+F4/80+CD11c-) and DCs (CD11c+) at 9 weeks after LPS injection. The mean values ± SD (n = 8 in A; n = 4 in B, C, D, and E; per group in the experiment; Student's t-test; *P < 0.05, **P < 0.01, ***P < 0.001) are shown.